“During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs.” - Martin Welschof, CEO of
EVENTS IN THE FIRST QUARTER
- (R)
CASI Pharmaceuticals reported positive interim Phase 1 data for BI-1206 in NHL inChina - Supply agreement signed with
AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence® (acalabrutinib) BioInvent regained the rights to immuno-oncology targets fromExelixis
EVENTS AFTER THE END OF THE PERIOD
- New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)
(R)= Regulatory event
FINANCIAL INFORMATION
First quarter 2024
- Net sales,
SEK 5.9 (16.2) million - Profit/loss after tax,
SEK -77.9 (-73.7) million - Profit/loss after tax per share before and after dilution,
SEK -1.18 (-1.12) - Cash flow from operating activities,
SEK -65.9 (-78.9) million - Liquid funds, current and long-term investments at the end of the period,
SEK 1,219.2 (1,546.4) million
The complete interim report is available for download below and on the company’s website www.bioinvent.com/investors/#financialreports.
About
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.
For further information, please contact:
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
© Modular Finance, source